Growth Metrics

Novavax (NVAX) Shares Outstanding (Weighted Average) (2016 - 2025)

Novavax has reported Shares Outstanding (Weighted Average) over the past 16 years, most recently at $162.0 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $162.0 million for Q4 2025, up 6.44% from a year ago — trailing twelve months through Dec 2025 was $162.0 million (up 6.44% YoY), and the annual figure for FY2025 was $162.0 million, up 6.44%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $162.0 million at Novavax, roughly flat from $161.8 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for NVAX hit a ceiling of $162.0 million in Q4 2025 and a floor of $73.0 million in Q1 2021.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $91.2 million (2023), compared with a mean of $110.5 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): increased 4.69% in 2022 and later surged 66.04% in 2024.
  • Novavax's Shares Outstanding (Weighted Average) stood at $74.4 million in 2021, then rose by 5.08% to $78.2 million in 2022, then rose by 28.89% to $100.8 million in 2023, then surged by 51.03% to $152.2 million in 2024, then increased by 6.44% to $162.0 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $162.0 million (Q4 2025), $161.8 million (Q3 2025), and $161.5 million (Q2 2025) per Business Quant data.